Overview

• Biotech firm's Q4 revenue missed analyst expectations

• Net income for Q4 missed analyst estimates

• Company refinanced term loan with Pharmakon Advisors for non-dilutive capital

Outlook

• Company expects 2026 JELMYTO sales between $97 mln and $101 mln

• Company anticipates submitting NDA for UGN-103 in second half of 2026

• UroGen forecasts 2026 operating expenses at $240 mln to $250 mln

Result Drivers

• ZUSDURI LAUNCH - ZUSDURI achieved net sales of $15.8 mln in 2025, reflecting initial launch period ahead of permanent J Code

• JELMYTO SALES GROWTH - JELMYTO achieved net product sales of $94 mln in 2025, representing a 7% year-over-year growth

• UGN-103 TRIAL SUCCESS - UGN-103 demonstrated a 77.8% three-month complete response rate in the UTOPIA trial

Company press release: ID:nGNX2z4KfB

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Urogen Pharma Ltd is $34.00, about 56.7% above its February 27 closing price of $21.70

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)